Boehringer Ingelheim International GmbH Boehringer Ingelheim invests in innovative peptide research and collaborates on GLP-1 related compounds, focusing on improving treatment outcomes for metabolic disorders
What new research on GLP-1s and migraines found In a 12-week study published in Headache: The Journal of Head and Face Pain , researchers tracked adults living with both obesity and chronic migraines who added the GLP-1 medication liraglutide (brand name Victoza) to their usual migraine treatment
Send your logo and brand colors and we build a compliant label on our proven layout, then fill and ship under your name
Retail pharmacies often interface with CoverMyMeds: when a claim rejects for PA required, the pharmacist can log into the CoverMyMeds portal and see the same form pre-populated with the prescription details
Standard pills often fall short because they cannot survive the journey through your digestive system
Moreover, the availability of multiple effective obesity pharmacotherapies with different mechanisms of action will provide clinicians the opportunity to select treatments based on patient preference, underlying comorbidities, medication safety profile and treatment response, with an aim to achieve the individualised WL targets, improve the overall health and/or the quality of life [7]
